Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Osugacestat · AL-101, BM-0018

Small molecule · Inhibitor of gamma secretase · developed by Alector

Phase 1 Most advanced trial (none active)

ALEC Developer

1 Registered trials

What is Osugacestat?

Osugacestat is a small-molecule gamma secretase and pan-Notch inhibitor. It binds gamma secretase and blocks cleavage that activates Notch receptors, which may inhibit proliferation of tumor cells with an overly active Notch pathway.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AL-101, BM-0018
Drug type: Small molecule
Targets: gamma secretase
Mechanism: Inhibitor of gamma secretase
Pathways: Notch signaling
Developer: Alector Inc. (ALEC)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1
UNII: DRL23N424R

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04111666	Phase 1	Healthy	Completed	ALEC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy

More from Alector

AL002 Phase 2 AL003 Phase 1 GSK4527226 Phase 2

Sources

NCI Thesaurus

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALEC page.

Follow ALEC, the company behind Osugacestat

See ALEC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALEC catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z